The global anastomosis devices market size was valued at USD 15.74 million in 2016. It is anticipated to expand at a CAGR of 5.2% over the forecast period. Rising surgical procedures along with growing incidence of cardiovascular and gastrointestinal diseases are the key trends escalating market growth.
According to statistics published by Medistim, on an average, more than 700,000 coronary artery bypass graft (CABG) and 600,000 vascular procedures are performed every year globally. According to HonorHealth, nearly 500,000 CABG procedures are performed every year in the U.S., making it one of the nation's most common major operations, thereby fuelling the demand for anastomotic devices.
Introduction of technologically advanced products providing better patient outcome is another factor driving the market. Some of the potential benefits of these products include reduced chances of vessel leakage, stenosis, and occlusion. Anastomosis performed using this device is 50% stronger than sutures, preventing vessel collapse and assuring patency.
Anastomosis devices are helpful in simplifying anastomosis procedure and minimizing surgery time. The aforementioned benefits are expected to provide a significant boost to the market worldwide.
Furthermore, presence of supportive regulatory framework is contributing to the growth of the market. Rising reimbursement coverage for CABG procedures is projected to stoke the adoption of anastomosis devices by surgeons. For instance, Medicare Part B covers coronary artery bypass graft surgery, coronary angioplasty, valve repair & replacement, and other comprehensive cardiac rehabilitation (CR) programs.
The disposable segment held the largest revenue share in the market in 2016, owing to the availability of an array of disposable anastomotic products and greater market penetration. Majority of key players are involved in the production of disposable type of products.
These products reduce the risk of surgical site infections (SSI), cross-contamination, and other healthcare-associated infections (HAI). Another advantage of disposable anastomotic devices over reusable ones is that they do not require reprocessing between consecutive uses, thereby reducing reprocessing cost and speeding up the entire process. This segment is poised to post a healthy growth rate owing to the aforementioned benefits.
Reusable anastomotic device is an emerging segment. It is likely to rise at a lucrative rate over the forecast period, owing to the development of technologically advanced products and rising need to reduce biomedical waste.
Certain single-use/disposable products are associated with high production cost, which consequently increases the selling price of these instruments. Adoption of reusable items could be an effective way of curbing higher prices. Moreover, cost of reprocessing and decontamination of reusable products is less as compared to the production of disposable anastomotic devices. Owing to the aforementioned factors, the segment is estimated to register the highest CAGR during the forecast period.
Cardiovascular surgery was the most prominent application segment in 2016. According to WHO, 17.7 million people died from CVD in 2015, which represented 31.0% of all deaths in the world. Rising prevalence of CVD is contributing to the increase in the number of heart surgeries such as CABG (coronary bypass graft surgery).
According to the article “CABG Versus PCI” published by NCBI in 2015, CABG procedures have an overall survival benefit and better patient outcome as compared to percutaneous coronary intervention (PCI) and treatment with drug-eluting stents in individuals affected by multivessel coronary artery disease. Hence, surgery is crucial for the treatment of such life-threatening diseases, thereby increasing adoption of anastomosis devices in these surgeries.
The gastrointestinal surgery segment, comprising colorectal surgeries and large bowel resections, is anticipated to witness tremendous growth over the forecast period, owing to the increasing prevalence of colorectal cancer and other gastrointestinal diseases, which require bowel resection. According to the Agency for Healthcare Research and Quality (AHRQ), around 320,000 colorectal surgeries and 460,000 cholecystectomy procedures are performed every year in the U.S.
Prevalence of colorectal cancer is increasing in Asia Pacific, owing to which the anastomosis devices market holds phenomenal potential in the region. For instance, according to estimates provided by the Center for Cancer Control and Information Services, National Cancer Center Japan, around 149,500 people were affected by colorectal cancer in 2017, making it the second most common cancer in Japan.
It also states that East Asian countries such as Japan, China, South Korea, and Singapore exhibited a two to four-fold increase in incidence over the last decade. Moreover, a large number of products for use in gastrointestinal anastomosis are expected to be introduced in the market over the forecast period, thereby providing lucrative growth platform to the market in near future.
North America accounted for the largest revenue share in 2016. Increasing prevalence of cardiovascular diseases and growing number of R&D collaborations carried out by major players in the region are projected to stimulate the growth of the region. For instance, in August 2016, Dextera Surgical Inc. entered into a joint development program with Intuitive Surgical, Inc. for developing a novel surgical stapler for the latter’s da Vinci Surgical System.
Furthermore, growing access to medical assistance, increasing awareness regarding CVD and CHD, rising disposable income, and highly established R&D infrastructure are key factors contributing to the growth of the regional market. Favorable healthcare reimbursement policies pertaining to CABG procedures, along with other factors mentioned, are poised to help the region maintain dominance until 2025. For instance, in 2016 Centers for Medicare & Medicaid Services (CMS) took steps to implement and grow mandatory bundled payments for CABG procedures in an attempt to increase quality, lower costs, and provide more care coordination among hospitals.
Asia Pacific is likely to register the highest CAGR over the forecast period. Japan, China, and India are the key contributors to the APAC market. The regional market is estimated to experience the fastest growth during the forecast period, owing to improving economic conditions, growing healthcare awareness, and increasing aging population in this region. Aged people are more susceptible to cardiovascular and gastrointestinal diseases, thereby presenting a huge target population for the industry.
Rising interest of companies to expand their presence in the region coupled with growing demand for anastomosis devices is anticipated to drive the market. Additionally, increasing research & development activities and soaring healthcare expenditure are working in favor of the regional market.
Some of the major players in the market are Medtronic; LivaNova PLC; MAQUET Holding B.V. & Co. KG.; Dextera Surgical Inc.; Vitalitec Internaional Inc.; Synovis Micro Companies Alliance, Inc.; and Ethicon US, LLC. Spiraling demand for better products and increased patient outcomes are resulting in the high competitive rivalry in the market.
The key players are involved in various strategies such as mergers & acquisitions, new product developments, collaborations & partnerships, and expansion strategies to improve their market penetration. For instance, in January 2017, Ethicon Endo-Surgery, Inc. acquired Megadyne Medical Products, Inc. in order to expand its advanced energy portfolio, including powered circular stapler.
Anastomosis devices are classified as class II medical devices owing to which the regulatory framework is not very stringent. These devices require only the manufacturer’s declaration of device safety and effectiveness before the sale and are not subjected to in-depth regulatory scrutiny. As the entry barriers to this market are less, the threat of new entrants is high, which thereby leads to increased competition. As a result, competitive rivalry in the market is expected to remain high throughout the forecast period.
Report Attribute |
Details |
Market size value in 2020 |
USD 19.19 million |
Revenue forecast in 2025 |
USD 24.84 million |
Growth Rate |
CAGR of 5.2% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product type, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; Japan; China; India; Brazil; Mexico; South Africa |
Key companies profiled |
Medtronic; LivaNova PLC; MAQUET Holding B.V. & Co. KG.; Dextera Surgical Inc.; Vitalitec Internaional Inc.; Synovis Micro Companies Alliance, Inc.; Ethicon US, LLC |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global anastomosis devices market report on the basis of product type, application, and region:
Product Type Outlook (Revenue, USD Million, 2014 - 2025)
Disposable
Reusable
Application Outlook (Revenue, USD Million, 2014 - 2025)
Cardiovascular Surgery
Gastrointestinal Surgery
Others
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
The U.K.
Germany
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
The Middle East and Africa
South Africa
b. The global anastomosis devices market size was estimated at USD 18.25 million in 2019 and is expected to reach USD 19.19 million in 2020.
b. The global anastomosis devices market is expected to grow at a compound annual growth rate of 5.2% from 2019 to 2025 to reach USD 24.84 million by 2025.
b. North America dominated the anastomosis devices market with a share of 40.71% in 2019. This is attributable to the increasing prevalence of cardiovascular diseases, growing access to medical assistance, increasing awareness regarding CVD and CHD, rising of disposable income and growing number of R&D collaborations carried out by major players.
b. Some key players operating in the anastomosis devices market include Medtronic; LivaNova PLC; MAQUET Holding B.V. & Co. KG.; Dextera Surgical Inc.; Vitalitec Internaional Inc.; Synovis Micro Companies Alliance, Inc.; and Ethicon US, LLC.
b. Key factors that are driving the anastomosis devices market growth include rising surgical procedures along with growing incidence of cardiovascular and gastrointestinal diseases, technologically advanced products, presence of supportive regulatory framework and increasing reimbursement coverage.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.